Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

23 Jul 2018

Abstract excerpt

BRD4 is a transcriptional co-activator functioning to recruit regulatory complexes to acetylated chromatin. A subset of High-grade Serous Ovarian Cancer (HGSOC) patients are typified by focal, recurrent BRD4 gene amplifications. Despite previously described cancer dependencies, it is unclear whether BRD4 amplification events are oncogenic in HGSOC. We find that physiologically relevant levels of expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30036377
DOI: 10.1371/journal.pone.0200826

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitorsPMID 30036377Read ↗

The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesisSemantic proximity Read ↗

BRD4 and Cancer: going beyond transcriptional regulationSemantic proximity Read ↗

Bromodomain inhibitor treatment leads to overexpression of multiple kinases in cancer cellsSemantic proximity Read ↗

BRD4: New hope in the battle against glioblastomaSemantic proximity Read ↗

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1Semantic proximity Read ↗

Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in MitosisSemantic proximity Read ↗

Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targetsSemantic proximity Read ↗

BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 SignalingSemantic proximity Read ↗

Post-Translational Modifications of BRD4: Therapeutic Targets for TumorSemantic proximity Read ↗

BET inhibitors as novel therapeutic agents in breast cancerSemantic proximity Read ↗

BRDT promotes ovarian cancer cell growthSemantic proximity Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.